Press

SciSparc Ltd. Announces Additional Positive Results for the Cocaine Addiction Treatment of its Psychedelic-based Pharma Collaboration with Clearmind Medicine Inc.

Aug 26 • 3 min read

SciSparc Ltd. (Nasdaq: SPRC), a specialty clinical-stage pharmaceutical company focusing on the development of therapies to treat disorders of the central nervous system (the “Company” or “SciSparc”), today announced additional positive pre-clinical results of its Psychedelic-based Pharma Collaboration for treatment for cocaine addiction using MEAI, a novel psychedelic molecule of Clearmind Medicine Inc. (“Clearmind”) (CSE:…

PSYC’s Bonfire Platform Development Progresses; Will Host Free Virtual Community Event on August 29th

Aug 26 • 5 min read

PSYC Corporation (OTCPink: PSYC), a multimedia leader focused on the emerging psychedelic and cannabis sectors, is proud to announce the Company, in partnership with Digital Acorn Ltd., continues to progress with the development of its Bonfire project (f/k/a “PsycheDev”). The companies, through Psychedelic Spotlight, will host their second virtual community-wide event on August 29, 2022,…

PSYC Appoints COO for Wholly Owned Subsidiary, Spotlight Media Corp.

Aug 26 • 6 min read

PSYC Corporation (OTCPink: PSYC), a multimedia leader focused on the emerging psychedelic and cannabis sectors, is proud to announce the appointment of Sacha G. Hebbert as Chief Operating Officer of the Company’s wholly owned subsidiary, Spotlight Media Corporation, along with the official launch of SMC’s new corporate website, www.spotlightmediacorp.com. PSYC incorporated and launched SMC earlier this year with the intent of…

Cybin: Clinilabs Granted Schedule I DEA License for CYB003 Phase 1/2a First-In-Human Clinical Trial – Form 6-K

Aug 26 • 4 min read

Cybin Inc. (NEO: CYBN) (NYSE American: CYBN), a biopharmaceutical company focused on progressing “Psychedelics to TherapeuticsTM”, and its partner Clinilabs Drug Development Corporation, a global, full-service contract research organization with deep expertise in central nervous system drug development, today announced that the U.S. Drug Enforcement Agency (“DEA”) has granted a Schedule I license to support…

BetterLife Lead Drug (BETR-001) Promotes Structural Neural Plasticity with Possible Nootropic Effects Similar to That of LSD Without Hallucinogenic Side Effects

Aug 25 • 2 min read

BetterLife Pharma Inc. (CSE: BETR | OTCQB: BETRF | FRA: NPAU), is an emerging biotech company focused on the development and commercialization of cutting-edge treatments for mental disorders. A recent study, published in Experimental Neurology, has provided some new evidence that LSD has nootropic effects which are believed to be driven by neuroplasticity promotion. Researchers found that LSD increased neuroplasticity in…

Pages: 123456789101112131415161718192021222324252627282930313233343536373839404142434445464748495051525354555657585960616263646566676869707172737475767778798081828384858687888990919293949596979899100101102103104105106107108109110111112113114115116117118119120121122123124125126127128129130131132133134135136137138139140141142143144145146147148149150151152153154155156157158159160161162163164165166167168169170171172173174175176177178179180181182183184185186187188189190191192193194195196197198199200201202203204205206207208209210211212213214215216217218219220221222223224225226227228229230231232233234235236237238239240241242243244245246247248249250251252253254255256257258259260261262263264265266267268269270271272273274275276277278279280281282283284285286287288289290291292293294295296297298299300301302303304305306307308309310311312313314315316317318319320321322323324325326327328329330331332333334335336337338339340341342343344345346347348349350351352353354355356357358359360361362363364365366367368369370371372373374375376377378379380381382383384385386387388389390391392393394395396397398399400401402403404405406407408409410411412413414415416417418419420421422423424425426427428429430431432433434435436437438439440441